<DOC>
	<DOCNO>NCT01027650</DOCNO>
	<brief_summary>This study evaluate safety efficacy single intravitreal injection AGN208397 treat Macular Edema associate Retinal Vein Occlusion . This study conduct two stage : Stage 1 enroll approximately 21 subject receive single open label intravitreal injection either 75 ug , 300 ug , 600 ug 900 ug AGN208397 follow 12 month post treatment ; base Stage 1 result , Stage 2 enroll approximately 96 subject receive single mask intravitreal injection one three dos AGN208397 OzurdexÂ® follow 12 month post treatment .</brief_summary>
	<brief_title>Safety Efficacy AGN208397 Treatment Macular Edema Associated With Retinal Vein Occlusion ( RVO )</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>macular edema due retinal vein occlusion visual acuity study eye 20/320 20/40 cataract surgery Lasik within 3 month prior study Day 1 anticipate need cataract surgery study period ( 12 month ) use injectable drug study eye within 2 month prior day 1 active eye infection either eye visual acuity nonstudy eye 20/200 worse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>